Aerovid Project

Startpagina
België
Liège
Aerovid Project

The aim of AEROVID project is the development of cyclodextrin-based inhaled therapies for the management of infection-induced respiratory disorders.

03/03/2023

Radiomics is a next generation Liege-based imaging research organisation (Radiomics, LégiaPark) and focuses on Artificial Intelligence (AI)-powered healthcare, led by Chief Executive Officer, Wim Vos.

Within the Aerovid Project, Radiomics aims to develop an automated AI-algorithm based solution which will strengthen Radiomics’ abilities to detect and correctly classify Ground-Glass Opacities and airway remodeling in lung CT scans of patients presenting infection-induced pulmonary diseases such as COVID-19 (abCOV) (Sébastien GOFFART, Flore Belmans, Inês Pinho).

The experience gained during this project will propel Radiomics’ expertise in developing AI clinical tools and understanding respiratory medicine to new heights.

24/02/2023

Aquilon Pharma, a spin-off of the University of Liege, founded in 2013 by Professors Didier Cataldo and Brigitte Evrard and leaded by Paul Maes, CEO has its laboratories in the technology incubator ‘The LABS by WSL’ located in Liege Science Park (https://lnkd.in/e47ZwPtt).

Aquilon's overall targets in the AEROVID project, under the coordination of Dr Natacha Rocks are not only to extend the indications of AQ’s drug products to inflammatory lung diseases induced by viral or bacterial infections but also to consolidate its R&D capacities (18 jobs by 2030), create a new untapped market (> 3 billion euros), build a manufacturing plant (extension of an existing project) (59 jobs by 2030) and possibly create a sales team for Be-Lux (40 jobs by 2030).

A very ambitious project!

23/02/2023

Member news! Aquilon Pharma is proud to announce that its AEROVID Project has been awarded a €2.3 million collaborative research grant from the Walloon Government and BioWin - The Health Cluster of Wallonia.

You can now follow the progress of the multidisciplinary AEROVID project, which federates knowledge in the fields of cyclodextrin-based inhaled therapies, artificial intelligence tools to identify and quantify pulmonary abnormalities as well as experimental models focusing on cellular and molecular actors implicated in infection-induced respiratory disorders.

Natacha Rocks, AEROVID Project coordinator, Aquilon Pharma, states: “We are excited and proud to advance this promising disease management solution for the millions of people suffering from infection-induced respiratory diseases.”

👉 Read the full release: https://lnkd.in/ekDbCj8C

Post from BioWin's LinkedIn : https://www.linkedin.com/feed/update/urn:li:activity:7032342400983269376/

22/02/2023

The objectives of the AEROVID project are threefold:
- Develop a comprehensive knowledge on cellular and molecular mechanisms driving host cell infection, subsequent inflammation and consequent chronic alterations and exacerbation episodes in infection-induced respiratory disorders,
- Develop improved and effective inhaled therapies for the treatment of infection-induced respiratory diseases,
- Develop a non-invasive artificial intelligence tool to correctly identify and diagnose respiratory disorders & assess the efficacy and safety of therapeutic strategies.

The strength of the project lies in the federation of pre-existing know-how, notably cyclodextrin-based formulation technology (Aquilon Pharma), advanced image acquisition and analysis (Radiomics, The Center for Microscopy and Molecular Imaging) and the development of experimental models of infection-induced respiratory diseases (https://lnkd.in/e7VfizfP, https://lnkd.in/e4wCPGjG).

21/02/2023

Aquilon Pharma (Aquilon Pharma, Paul J. Maes) announces that the AEROVID project (duration: 30 months) was awarded a €2,3 million collaborative research grant from Belgium’s Walloon Region government in coordination with the Region’s Health Competitiveness cluster BioWin - The Health Cluster of Wallonia.

For AEROVID, to share their know-how, Aquilon Pharma, as project coordinator, recruited Radiomics (Radiomics, Wim Vos) as well as fellow Wallonia-based academic partners, Université de Liège (GIGA - Université de Liège, Thomas Marichal, https://lnkd.in/dyxHnnZN, Daniel Desmecht, Julien Guiot), The Center for Microscopy and Molecular Imaging (Natacha Lourette, Gilles Doumont, Louise CONRARD) established on Université libre de Bruxelles (Université libre de Bruxelles) and Université de Mons (UMons).

The aim of the project is the development of cyclodextrin-based inhaled therapies for the management of infection-induced respiratory disorders.

20/02/2023

Aquilon Pharma (https://lnkd.in/dCr7UwNc, Paul J. Maes and Damien Thiéry) announces that you can now follow the progress of the project 'Aerovid', granted by the Walloon Government and BioWin - The Health Cluster of Wallonia.

Go to https://lnkd.in/ed9G2tBy to learn more about cyclodextrin-based inhaled therapies, artificial intelligence tools to identify and quantify pulmonary abnormalities as well as experimental models focusing on cellular and molecular actors implicated in infection-induced respiratory disorders.

Adres

Quai De La Boverie 59
Liège
4000

Website

https://www.linkedin.com/company/aerovid-project/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Aerovid Project nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Snelkoppelingen

Type

Medisch en gezondheid